Comprehensive immunogenicity data of individualized neoantigen therapeutic vaccine (INTV) TG4050, from the randomized Phase I study in operable Head and Neck Squamous Cell Carcinoma (HNSCC) patients, to be presented at SITC 2025
New TG4050 data further validate its mechanism of action and potential to reduce risk of relapse presented at ASCO 2025
First immunogenicity data in the ongoing Phase II trial in operable HNSCC expected in H2 2026
Strasbourg, France, November 4, 2025, 5:50 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update on its lead asset TG4050 developed from its myvac® platform, upcoming plans, and its financial position as of September 30, 2025.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer